FI3137094T3 - Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen - Google Patents
Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen Download PDFInfo
- Publication number
- FI3137094T3 FI3137094T3 FIEP15720060.1T FI15720060T FI3137094T3 FI 3137094 T3 FI3137094 T3 FI 3137094T3 FI 15720060 T FI15720060 T FI 15720060T FI 3137094 T3 FI3137094 T3 FI 3137094T3
- Authority
- FI
- Finland
- Prior art keywords
- aluminum
- use according
- administered
- oxyhydroxide
- aluminum salt
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 10
- 230000002265 prevention Effects 0.000 title claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 14
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical group O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 claims 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229960004906 thiomersal Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166388 | 2014-04-29 | ||
| EP14166355 | 2014-04-29 | ||
| PCT/EP2015/059341 WO2015165968A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3137094T3 true FI3137094T3 (fi) | 2023-03-20 |
Family
ID=53039897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15720060.1T FI3137094T3 (fi) | 2014-04-29 | 2015-04-29 | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11065273B2 (https=) |
| EP (2) | EP4209222A1 (https=) |
| JP (1) | JP2017515812A (https=) |
| KR (1) | KR102506460B1 (https=) |
| CN (1) | CN106659736A (https=) |
| AU (1) | AU2015254665A1 (https=) |
| CA (1) | CA2946931A1 (https=) |
| DK (1) | DK3137094T3 (https=) |
| FI (1) | FI3137094T3 (https=) |
| PL (1) | PL3137094T3 (https=) |
| PT (1) | PT3137094T (https=) |
| WO (1) | WO2015165968A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3137094T3 (pl) | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
| EP3137097B1 (en) * | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| EP3137093B1 (en) * | 2014-04-29 | 2017-09-13 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| JP4662719B2 (ja) * | 2002-04-19 | 2011-03-30 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | アルツハイマー病の処置のための免疫学的方法および組成物 |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| WO2009105641A2 (en) | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| AT506820B1 (de) | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| AT506819B1 (de) | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| EP2145898A1 (en) * | 2008-07-15 | 2010-01-20 | CHIESI FARMACEUTICI S.p.A. | Anti-amyloid immunogenic compositions, methods and uses |
| BR112012024708A2 (pt) * | 2010-03-29 | 2016-06-07 | Novartis Ag | composição de compostos orgânicos |
| GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| EP3137097B1 (en) | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| EP3137093B1 (en) | 2014-04-29 | 2017-09-13 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
| PL3137094T3 (pl) | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
-
2015
- 2015-04-29 PL PL15720060.1T patent/PL3137094T3/pl unknown
- 2015-04-29 CN CN201580029850.7A patent/CN106659736A/zh active Pending
- 2015-04-29 EP EP22211552.9A patent/EP4209222A1/en active Pending
- 2015-04-29 PT PT157200601T patent/PT3137094T/pt unknown
- 2015-04-29 FI FIEP15720060.1T patent/FI3137094T3/fi active
- 2015-04-29 KR KR1020167033324A patent/KR102506460B1/ko active Active
- 2015-04-29 JP JP2016565334A patent/JP2017515812A/ja active Pending
- 2015-04-29 EP EP15720060.1A patent/EP3137094B1/en active Active
- 2015-04-29 DK DK15720060.1T patent/DK3137094T3/da active
- 2015-04-29 CA CA2946931A patent/CA2946931A1/en not_active Abandoned
- 2015-04-29 US US15/307,246 patent/US11065273B2/en active Active
- 2015-04-29 WO PCT/EP2015/059341 patent/WO2015165968A1/en not_active Ceased
- 2015-04-29 AU AU2015254665A patent/AU2015254665A1/en not_active Abandoned
-
2021
- 2021-07-08 US US17/370,615 patent/US11857568B2/en active Active
-
2023
- 2023-11-20 US US18/514,612 patent/US20240148782A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3137094T3 (da) | 2023-02-27 |
| CA2946931A1 (en) | 2015-11-05 |
| CN106659736A (zh) | 2017-05-10 |
| KR20160145821A (ko) | 2016-12-20 |
| WO2015165968A1 (en) | 2015-11-05 |
| AU2015254665A1 (en) | 2016-11-10 |
| US20170049810A1 (en) | 2017-02-23 |
| EP3137094B1 (en) | 2022-12-07 |
| PT3137094T (pt) | 2023-03-09 |
| JP2017515812A (ja) | 2017-06-15 |
| US20220000908A1 (en) | 2022-01-06 |
| PL3137094T3 (pl) | 2023-03-13 |
| US11065273B2 (en) | 2021-07-20 |
| EP3137094A1 (en) | 2017-03-08 |
| US20240148782A1 (en) | 2024-05-09 |
| US11857568B2 (en) | 2024-01-02 |
| EP4209222A1 (en) | 2023-07-12 |
| KR102506460B1 (ko) | 2023-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201492021A1 (ru) | Антительный состав | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| EP2548552A3 (en) | Titration package for 1-amino-alkylcylohexanes | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| JP2018532806A5 (https=) | ||
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| JP2016534062A5 (https=) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| JP2017515812A5 (https=) | ||
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| SI3137093T1 (en) | Treatment and prevention of Alzheimer's disease | |
| MX2021015441A (es) | Formas cristalinas de cabotegravir de sodio. | |
| MX2019015480A (es) | Preparacion medicinal combinada para tratar infecciones virales. | |
| JP2017518275A5 (https=) |